中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.026 seconds)

    SELECTIVE INHIBITORS OF TUMOR-INITIATING CELLS
    2.
    发明申请
    SELECTIVE INHIBITORS OF TUMOR-INITIATING CELLS 审中-公开
    选择性的肿瘤启动抑制剂

    公开(公告)号：WO2012122015A2

    公开(公告)日：2012-09-13

    申请号：PCT/US2012/027474

    申请日：2012-03-02

    Applicant: IMMUNE DISEASE INSTITUTE, INC. ,  LIEBERMAN, Judy ,  PETROCCA, Fabio

    Inventor： LIEBERMAN, Judy ,  PETROCCA, Fabio

    IPC: G01N33/68 ,  C12N5/09 ,  C12Q1/68 ,  A61K48/00

    CPC classification number: C12Q1/6886 ,  A61K31/165 ,  A61K31/167 ,  A61K31/713 ,  A61K38/05 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N2500/10 ,  G01N2800/52 ,  G01N2800/56

    Abstract: Described herein are novel malignancy associated gene signature biomarkers, and assays and methods thereof, to classify prognosis or malignant potential of a cancer and identify cancer-initiating cells. The malignancy associated gene signature biomarkers, assays and methods described herein provide, in part, new methodologies to screen for novel drugs for treating cancers and tumors, such as, for example, triple-negative breast tumors. Using the assays and methods described herein proteasome inhibitors, histone deacetylase inhibitors, and glycolysis inhibitors, were identified as being highly effective in altering gene expression signatures specifically in malignant or cancer-initiating cells.

    Abstract translation: 本文描述了新的恶性肿瘤相关基因标记生物标志物及其测定方法，以分类癌症的预后或恶性潜能并鉴定癌症起始细胞。 本文所述的恶性肿瘤相关基因标记生物标志物，测定法和方法部分地提供筛选用于治疗癌症和肿瘤的新药的新方法，例如三阴性乳腺肿瘤。 使用本文所述的测定和方法，蛋白酶体抑制剂，组蛋白脱乙酰酶抑制剂和糖酵解抑制剂被鉴定为在改变恶性或癌症起始细胞中的基因表达特征方面是高度有效的。

    SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF
    4.
    发明申请
    SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF 审中-公开
    从合成，修饰的RNAs及其应用中可持续的多肽表达

    公开(公告)号：WO2011130624A2

    公开(公告)日：2011-10-20

    申请号：PCT/US2011/032679

    申请日：2011-04-15

    Applicant: IMMUNE DISEASE INSTITUTE, INC. ,  ROSSI, Derrick ,  WARREN, Luigi

    Inventor： ROSSI, Derrick ,  WARREN, Luigi

    IPC: C12N5/10 ,  C12N15/113 ,  C12N5/074 ,  C07H21/00

    CPC classification number: C12N5/0696 ,  C07K14/435 ,  C12N15/11 ,  C12N15/111 ,  C12N2310/14 ,  C12N2320/30

    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.

    Abstract translation: 本文描述了用于改变细胞表型的合成的，修饰的RNA，例如表达多肽或改变发育潜能。 因此，本文提供的是包含用于改变细胞或细胞的表型的合成的，修饰的RNA的组合物，方法和试剂盒。 包含合成的修饰的RNA的这些方法，组合物和试剂盒可用于在细胞或组织中表达所需的蛋白质，或将细胞的分化表型改变为另一种所需细胞类型的分化表型。

    THERAPEUTIC AND DIAGNOSTIC STRATEGIES
    6.
    发明申请
    THERAPEUTIC AND DIAGNOSTIC STRATEGIES 审中-公开
    治疗和诊断策略

    公开(公告)号：WO2010033822A2

    公开(公告)日：2010-03-25

    申请号：PCT/US2009/057506

    申请日：2009-09-18

    Applicant: IMMUNE DISEASE INSTITUTE, INC ,  LIEBERMAN, Judy ,  LAL, Ashish ,  CHOWDHURY, Dipanjan

    Inventor： LIEBERMAN, Judy ,  LAL, Ashish ,  CHOWDHURY, Dipanjan

    IPC: A61K31/7105 ,  A61P43/00

    CPC classification number: C12N15/113 ,  C12N15/111 ,  C12N2310/141 ,  C12N2320/11 ,  C12Q1/6806 ,  C12Q1/6809

    Abstract: The present invention encompasses the finding that microRNAs (miRNAs) regulate certain key proteins involved in DNA repair. In some embodiments, a miRNA suppresses levels and/or activity of one or more DNA repair proteins. In some such embodiments, such suppression renders cells hypersensitive to certain DNA damage agents (e.g., γ-irradiation and genotoxic drugs, among others). The present invention provides various reagents and methods associated with these findings including, among other things, strategies for treating cell proliferative disorders, certain diagnostic systems, etc.

    Abstract translation: 本发明包括微RNA（miRNA）调节参与DNA修复的某些关键蛋白质的发现。 在一些实施方案中，miRNA抑制一种或多种DNA修复蛋白的水平和/或活性。 在一些这样的实施方案中，这种抑制使细胞对某些DNA损伤剂（例如γ-照射和遗传毒性药物等）过敏。 本发明提供了与这些发现相关的各种试剂和方法，其中包括治疗细胞增殖性疾病，某些诊断系统等的策略。

    REGULATORS OF NFAT AND/OR STORE-OPERATED CALCIUM ENTRY
    10.
    发明申请
    REGULATORS OF NFAT AND/OR STORE-OPERATED CALCIUM ENTRY 审中-公开
    NFAT和/或存储操作的钙进入的调节剂

    公开(公告)号：WO2012048316A2

    公开(公告)日：2012-04-12

    申请号：PCT/US2011/055561

    申请日：2011-10-10

    Applicant: IMMUNE DISEASE INSTITUTE, INC. ,  RAO, Anjana ,  HOGAN, Patrick ,  SHARMA, Sonia

    Inventor： RAO, Anjana ,  HOGAN, Patrick ,  SHARMA, Sonia

    IPC: A61K48/00

    CPC classification number: C12N15/113 ,  C12N2310/14

    Abstract: Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca 2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of septin 4 (SEPT 4) and septin 5 (SEPT 5) proteins involved in the calcineurin/NFAT axis and T-cell activation.

    Abstract translation: 本发明的实施方案涉及通过抑制septin 4（SEPT 4）和septin 5（SEPT 5）的表达或活性来调节NFAT活性，调节储存操作的Ca 2+进入细胞并治疗和/或预防多动症或不适当的免疫应答。 参与钙调神经磷酸酶/ NFAT轴的蛋白质和T细胞活化。

Patent Agency Ranking